170 related articles for article (PubMed ID: 2551973)
21. Detection of primary Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease receiving immunoglobulin prophylaxis.
Okano M; Bashir RM; Davis JR; Purtilo DT
Am J Hematol; 1991 Apr; 36(4):294-6. PubMed ID: 1849350
[TBL] [Abstract][Full Text] [Related]
22. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization.
Berg LC; Copenhaver CM; Morrison VA; Gruber SA; Dunn DL; Gajl-Peczalska K; Strickler JG
Hum Pathol; 1992 Feb; 23(2):159-63. PubMed ID: 1310951
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus induced lymphoproliferative tumors in severe combined immunodeficient mice are oligoclonal.
Pisa P; Cannon MJ; Pisa EK; Cooper NR; Fox RI
Blood; 1992 Jan; 79(1):173-9. PubMed ID: 1309425
[TBL] [Abstract][Full Text] [Related]
24. Different Epstein-Barr virus expression in lymphomas from immunocompromised and immunocompetent patients.
Borisch-Chappuis B; Nezelof C; Müller H; Müller-Hermelink HK
Am J Pathol; 1990 Apr; 136(4):751-8. PubMed ID: 1691592
[TBL] [Abstract][Full Text] [Related]
25. The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA.
Hurley EA; Klaman LD; Agger S; Lawrence JB; Thorley-Lawson DA
J Virol; 1991 Jul; 65(7):3958-63. PubMed ID: 1645805
[TBL] [Abstract][Full Text] [Related]
26. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-associated lymphoproliferative disorders.
Purtilo DT; Strobach RS; Okano M; Davis JR
Lab Invest; 1992 Jul; 67(1):5-23. PubMed ID: 1320711
[TBL] [Abstract][Full Text] [Related]
28. Advances in the diagnosis and treatment of EBV-associated lymphoproliferative diseases in immunocompromised hosts.
Hanto DW; Najarian JS
J Surg Oncol; 1985 Dec; 30(4):215-20. PubMed ID: 3001429
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
30. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Noguchi K
Yakugaku Zasshi; 2019; 139(1):63-67. PubMed ID: 30606931
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus genome studies in Burkitt's and non-Burkitt's lymphomas in Uganda.
Olweny CL; Atine I; Kaddu-Mukasa A; Owor R; Andersson-Anvret M; Klein G; Henle W; de-Thé G
J Natl Cancer Inst; 1977 May; 58(5):1191-6. PubMed ID: 192894
[TBL] [Abstract][Full Text] [Related]
32. In situ hybridization for the detection of Epstein-Barr virus in central nervous system lymphomas.
Nakhleh RE; Manivel JC; Copenhaver CM; Sung JH; Strickler JG
Cancer; 1991 Jan; 67(2):444-8. PubMed ID: 1845947
[TBL] [Abstract][Full Text] [Related]
33. [Epstein-Barr virus (EBV) in lymphoproliferative diseases].
Tatusmi E; Yoneda N
Rinsho Ketsueki; 1991 Jun; 32(6):660-8. PubMed ID: 1653862
[TBL] [Abstract][Full Text] [Related]
34. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
35. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
Rowe M; Young LS; Crocker J; Stokes H; Henderson S; Rickinson AB
J Exp Med; 1991 Jan; 173(1):147-58. PubMed ID: 1845872
[TBL] [Abstract][Full Text] [Related]
37. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.
Kawa-Ha K; Ishihara S; Ninomiya T; Yumura-Yagi K; Hara J; Murayama F; Tawa A; Hirai K
J Clin Invest; 1989 Jul; 84(1):51-5. PubMed ID: 2544630
[TBL] [Abstract][Full Text] [Related]
38. [Expression of latent membrane proteins (LMP) of Epstein-Barr virus in malignant lymphomas].
Herbst H; Dallenbach F; Niedobitek G; Anagnostopoulos I; Hummel M; Finn T; Jautzke G; Müller-Lantzsch N; Stein H
Verh Dtsch Ges Pathol; 1991; 75():175-8. PubMed ID: 1724825
[TBL] [Abstract][Full Text] [Related]
39. Demonstration of Epstein-Barr virus in malignant non-Hodgkin's lymphomas.
Wutzler P; Färber I; Sauerbrei A; Helbig B; Wutke K; Rüdiger KD; Scheibner K; Brichàcek B; Vonka V
Oncology; 1986; 43(4):224-9. PubMed ID: 2425318
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
